Using a nonviral, electroporation-based gene transfection approach, we demonstrate the efficient and consistent transfection of two poorly immunogenic tumor cell lines: B16F10 melanoma and renal carcinoma (RENCA). Three genes, IL-12, angiostatin (AS), and an endostatin:angiostatin fusion protein (ES:AS) were subcloned into a DNA plasmid containing EBNA1-OriP, which was then transfected into B16F10 and RENCA cells. Significant levels of protein were secreted into the culture supernatants of transfected cells in vitro. Transfected tumor cells were injected subcutaneously into mice. All the three transgenes were capable of significantly delaying and reducing the formation of primary B16F10 and RENCA tumors, as well as B16F10 lung metastases. By day 11 postinjection, all control mice that received either mock-transfected or empty vector DNA-transfected B16F10 tumor cells had developed large primary tumors. In contrast, mice that received IL-12-transfected B16F10 cells did not develop appreciable tumors until day 17, and these were significantly smaller than controls. Similar results were observed for the RENCA model, in which only one of the IL-12 mice had developed tumors out to day 31. Expression of AS or ES:AS also significantly delayed and reduced primary tumors. Overall, ES:AS was more effective than AS alone. Furthermore, 25% of the AS mice and 33% of the ES:AS mice remained tumor-free at day 17, by which point all control mice had significant tumors. Mouse survival rates also correlated with the extent of tumor burden. Importantly, no lung metastases were detected in the lungs of mice that had received either AS or ES:AS-transfected B16F10 tumor cells and significantly fewer metastases were found in the IL-12 group. The consistency of our transfection results highlight the feasibility of directly electroporating tumor cells as a means to screen, identify, and validate in vivo potentially novel antiangiogenic and/or antineoplastic genes.
C
ancer biologists are faced with the daunting task of devising gene-based screening and validation protocols, in order to identify potentially novel antineoplastic therapeutics. These approaches must meet seemingly contradictory criteria. On the one hand, they must be sensitive and consistent enough to allow for any biologic response to be interpreted appropriately. However, they must also be reasonably rapid and cost-effective, so that researchers may be assured that adequate pools of candidates are examined. In addition, it is most desirable that they are compatible with already-established assays of gene function, both in vitro and in vivo.
The approach of directly transfecting tumor cells with cDNA might be useful for the screening of cDNA libraries for those genes with antitumor function in vitro (e.g. cell proliferation, adhesion, migration, etc.). Furthermore, by injecting the transfected tumor cells directly into mice, one would be able to readily compare the growth of primary and metastatic tumors. This can be developed into an in vivo diagnostic screening or validation protocol for studying previously uncharacterized or newly identified antitumor genes.
Transduction of tumor cells with viral vectors that deliver cytokines or other antitumor genes was initially established using GM-CSF-transfected B16F10 melanoma cells in a mouse model. 1 Other researchers have shown similar transgene expression mediated by retroviral or adenoviral vectors. [2] [3] [4] [5] [6] Viral vectors have also been used in pre-clinical studies to deliver antiangiogenic factors, such as endostatin (ES) or angiostatin (AS) to human, 6, 7 as well as mouse, [8] [9] [10] tumors. However, extra consideration must be given to the possibility of eliciting undesirable immune responses against viral antigens, particularly if the tumor cells are to be used in an in vivo experimental system, such as a murine tumor model. For example, Scholz et al 11 recently showed that T cells, when cocultured in direct cell contact with adenoviral vector transduced cells, undergo apoptosis. This finding may explain why adenoviral vector-modified tumor cells sometimes failed to elicit effective antitumor T-cell responses in vivo. More practical limitations of using viral vectors for gene screening purposes may also include the considerable cost and time/labor required to develop suitable vectors.
Nonviral transfection of tumor cells has also been extensively used to elicit consistent and efficient transgene expression. However, these studies have yielded somewhat mixed results, due to the fact that the transgene expression was typically transient and variable. Steiner and Barrack showed that cells forcedly expressing transforming growth factor beta (TGF-b) were functional in vivo, provided they first selected those stable clones producing the highest levels of gene product. 12 More recently, the chemokine MIP-1a was introduced into B16F10 cells by FuGENE6-mediated DNA transfection. 13 Again, the MIP-1a transgene was functional in vivo, after the authors had used chemical selection to obtain stable cell clones. 13 These studies have demonstrated the feasibility of evaluating transgene-induced antitumor effects mediated directly at the tumor cell level. Unfortunately, they required not only extensive time for the selection and generation of stable clones but, due to the fact that there was considerable variability in the level of transgene expression in these cells, only those stable cells producing the highest levels of gene expression were used. 12 In summary, transgene expression in tumor cell lines mediated by viral vectors or involving drug selection often contains significant variability. This may limit the suitability of these approaches for large-scale gene screening and rapid validation.
We set out to optimize an electroporation-based approach that could rapidly and, more importantly, efficiently and consistently transfect two murine tumor cells: renal carcinoma (RENCA) and B16F10 melanoma with plasmid DNA. To validate the system, we chose two well-characterized antiangiogenic and antineoplastic genes, namely interleukin-12 (IL-12) and AS. We also tested an endostatin:angiostatin fusion protein (ES:AS), to determine whether this construct was as or more effective than AS alone. It is known that electroporation, in the absence of selection, typically results in transient expression of the transgene just like other nonviral methods.
14 However, DNA plasmids carrying the EBNA1-oriP region from EBV have been shown to improve the duration and level of transgene expression. 15, 16 Since we have previously shown that this is indeed the case for electroporation-mediated delivery of plasmid DNA into mammalian cells, 15, 17 the transgenes used in the present study were subcloned into a similar DNA vector containing EBNA1-oriP. Transgene function was evaluated in vitro in an endothelial cell tube formation assay and in vivo in two subcutaneous murine tumor models. For all the three transgenes that we evaluated, functional gene products were found, both in vitro and in vivo. Furthermore, by combining electroporation with optimized vector design for longer transgene expression, we eliminated the need for long periods of stable clone selection, which appears to improve the overall consistency in transgene expression.
Materials and methods

Cells
Murine renal carcinoma (RENCA) and melanoma (B16F10) cells were generously provided by Kirk Volker (EntreMed, Inc.). B16F10 cells were maintained in DMEM (BioWhittaker) supplemented with 10% fetal bovine serum, 200 mM L-glutamine, 1 Â nonessential amino acids, and 2 Â MEM vitamin mixture (each from Hyclone). RENCA were maintained in RPMI (BioWhittaker) supplemented with the same additives as B16F10 cells, with the addition of 100 mM sodium pyruvate. Murine embryonic fibroblast 10T1/2 (ATCC cat # CCI-226) cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and were cultured in complete medium consisting of Dulbecco's MEM (DMEM) supplemented with L-glutamine (2 mM), penicillin (100 U/mL), streptomycin (100 mg/mL), and 10% fetal bovine serum (FBS, HyClone, Logan, UT). Primary human umbilical vein endothelial cells (HUVEC) were maintained in M199 media (Cambrex) supplemented with 2% FBS and endothelial cell growth factors (SingleQuots, Cambrex).
DNA subcloning
pGEG.mIL12 and pGEG.eGFP were kind gifts from Dr Osam Mazda and were described previously. 18 cDNA encoding human AS (K1-3) and the ES-AS fusion protein were generous gifts from EntreMed, Inc. Each was amplified by PCR. A BglII restriction site was incorporated into the 5 0 end primer and a NotI restriction site was included in the 3 0 end primer immediately after the stop codon. Then, the PCR product was cleaned and digested with BglII and NotI and subcloned into the same sites of the EBNA1-oriP-containing plasmid backbone separately. For a schematic representation of the DNA plasmids used in this study, please see Figure 1 . All plasmids were propagated in E. coli strain DH5a (Invitrogen) and purified using endotoxin-free T-10000 columns from Qiagen (Chatsworth, CA, USA). Each batch of plasmid DNA was routinely checked for its A260/A280 ratio (1.75-1.9), endotoxin level (3-22 EU/ mg), and percentage of super coil population (80-95%).
Electroporation
Tumor cells were collected by trypsinization, washed once with electroporation buffer (125 mM KCl, 15 mM NaCl, 1.2 mM MgCl 2 , 3 mM glucose, 25 mM HEPES, pH 7.4) and resuspended at a final concentration of 50e6 cells/mL in the electroporation buffer. DNA was added to each cell sample at a final concentration of 200 mg/mL. Cells were transfected using sterile, reusable cuvettes with goldplated electrodes spaced 3 mm apart. The cuvettes were placed into the MaxCyte GT System, which was programmed with the following parameters: 2 kV/cm, 400 mseconds pulse length, 4 square pulses with a 1 second interval. Immediately following electroporation, cell samples were transferred to eppendorf tubes and incubated at 371C for 20 minutes. Cells were then plated back to tissue culture flasks in complete medium and incubated overnight allowing for transgene expression.
Flow cytometry
The transfection efficiency was analyzed by flow cytometry using eGFP as a marker gene. FACS was also used to analyze cell viability, which was indicated by propidium iodide (PI) negatively stained cells. Cells were collected by trypsinization 24 hours post transfection. Any floating/dead cells were also pooled with the adherent cells. Cells were washed once with PBS and incubated with PI at 1 mg/mL immediately prior to flow cytometric analysis. Forward-and side-scatter gating was used to identify the cell populations; however, all cells were included in the analyses. Untransfected cells served as controls. The FACScan flow cytometer and CellQuest software were from Becton Dickinson Immunocytometry Systems (San Jose, CA).
ELISA
At various time-points, the conditioned tissue culture supernatants from transfected cells were collected, sterile filtered, and stored at À201C until use. For determining mIL-12 expression, commercially available ELISA kits (R&D Systems) were used according to the manufacturerprovided protocol. For AS and ES:AS fusion protein detection, 96-well Immunlon 4 plates (Dynatech Laboratories) were coated overnight with 50 mL monoclonal antibody to human plasminogen (10 mg/mL; Biodesign International). Coated wells were blocked with 3% nonfat milk/PBS for 30 minutes before adding samples. For detection, 50 mL HRP-conjugated goat anti-human plasminogen (0.4 mg/mL; Accurate Chemical & Scientific Corp) was used, followed by the ABTS peroxidase reaction (Kirkegaard & Perry Laboratories). The sensitivity of these assays is o15 pg/mL for mIL-12 and 1.65 ng/mL for AS. Results were normalized to the number of cells in each well of a tissue culture plate.
In vitro HUVEC tube formation assay 10T1/2 murine embryonic fibroblasts were transfected with various transgenes as described above. As controls, 10T1/2 cells were mock transfected (no DNA) or transfected with a DNA plasmid encoding for eGFP (peGFP) as an irrelevant control gene. At 24 hours posttransfection, 5e4 transfected fibroblasts were seeded onto transwell inserts that had 8 mm pore sizes (Costar). The transwell inserts were then placed atop wells of a 24-well culture plate containing 1e4 human umbilical vein endothelial cells (HUVEC) growing on 0.5% gelatin, such that the two cell types shared a common supernatant without direct cell contact. bFGF (R&D Systems) was added at a final concentration of 5 ng/ml to induce HUVEC tube formation. 19 After 2 days, bright-phase images were captured using a digital camera attached to an inverted microscope. A computer-assisted imaging program (Image Pro Plus, Media Cybernetics Inc.) and statistical software (Microsoft Excel) was used to quantitate the connectivity and total length of the tubes formed by HUVEC. As controls, wells to which no bFGF was added were included to illustrate the baselines.
Mouse tumor models
C57BL6 and Balb/C male mice (6 weeks of age) were obtained from The Jackson Laboratories (Bar Harbor, ME, USA). Mice were cared for under an approved Institutional Animal Care and Use Committee (IACUC) protocol.
For tumor injections, 5e5 transfected RENCA or 1e5 transfected B16F10 cells were injected subcutaneously into the backs of mice. As controls, an equal number of untransfected or mock-transfected (no DNA) tumor cells were injected into mice. Primary tumor areas were measured twice a week using mechanical calipers. Tumor volumes were calculated by the formula v ¼ pab 2 /6, where a is the longest diameter and b is the next longest diameter perpendicular to a. 20, 21 For the determination of B16F10 lung metastases, mice were killed 23 days post tumor cell injection and the lungs were collected. The number of metastases was counted using a dissecting microscope.
Statistical analyses
Students paired T-test (Microsoft Excel) was used to determine the significance between animal groups. The number of animals in each experiment ranged between 6 and 8 mice/group. Results were considered to be significant for Po.05 values.
Results
Efficient transfection of RENCA and B16F10 cells Figure 1 summarizes the DNA constructs utilized in this study. eGFP was first used as a marker gene, since it enabled us to determine cell transfection efficiency as well as overall cell viability by flow cytometry, where dead cells were stained positively with PI. After an initial period of optimizing the conditions used to transfect cells (i.e. field strength, pulsing conditions, DNA, and cell concentration), we achieved an 80% transfection efficiency for both B16F10 and RENCA tumor cell lines (Fig  2) , while the overall cell viability (80-90%) was maintained (as determined by PI exclusion). Similar results were observed in at least three separate experiments, demonstrating the consistency of this approach.
We next determined the level of protein secretion for three different gene products: mIL-12, AS, and an ES:AS fusion protein. ELISA analysis of the transfected cell conditioned supernatants was performed to determine the amount of protein produced in each sample, which was then normalized to the total number of cells. As shown in Figure 3 , significant levels of all the three transgene products were detected by 24 hour post-transfection. Furthermore, the expression of IL-12, AS, and ES:AS sustained up to 7 days post-transfection, when cells became too confluent and started peeling off from the plates. As controls, cells were mock-transfected with an empty DNA vector, which contained no insert. The supernatants of cells transfected with this control contained no detectable IL-12 or AS (Fig 3) .
Functional transgene expression in vitro
In order to demonstrate the functional expression of transgenes, we used an in vitro model of angiogenesis, an endothelial cell tube formation assay. 19 In this assay, human umbilical vein endothelial cells (HUVEC) growing on 0.5% gelatin can be induced by bFGF treatment to form morphologically distinct tubes, which represent primitive vessels. We seeded 5e4 transfected 10T1/2 murine embryonic fibroblasts onto Transwell inserts containing an 8 mm pore size and placed this insert atop wells containing the HUVEC. In this setup, the transfected fibroblasts share a common supernatant with the HUVEC, but do not actually touch them. FGF (5 ng/ml) was added to the HUVEC at the same time as the transfected fibroblasts. After 2 days, the Transwells were removed and the extent of HUVEC tube formation was quantitated. Two measures of HUVEC tubes were determined: connectivity/branch length as well as total outgrowth length (Fig 4) .
Transgenic expression of AS caused a significant decrease in the formation of HUVEC tubes, as compared to mock-transfected (no DNA) and irrelevant transgene (eGFP) controls (Fig 4) . These results were also significant to conditions in which no fibroblasts were seeded onto the Transwell (medium only). When the extent of inhibition was compared to wells in which no bFGF was added (thus reflecting a baseline), it was found that AS expression inhibited both tube connectivity as well as total outgrowth length by approximately 50% of the difference between no bFGF and the positive controls in which bFGF is present at 5 ng/ml (no cells, no DNA or irrelevant DNA). These results demonstrate that functional gene products, generated by transiently transfected cells, may be suitable for established in vitro gene discovery protocols, including antiangiogenesis assays.
Functional transgene expression in vivo
In order to determine whether transfected transgenes were capable of exerting a biological effect in vivo, we used two well-established murine tumor models. Both RENCA and B16F10 cells, when injected subcutaneously into syngeneic mice, predictably grow into measurable primary tumors over a period of 1-3 weeks. B16F10 tumors are also well known to metastasize to the lung. 22 We therefore implanted transfected RENCA or B16F10 tumor cells subcutaneously, and monitored three different readouts of transgene efficacy: (1) primary tumor size, (2) number of lung metastases, and (3) overall mouse lethality. All the three transgenes that we evaluated (AS, ES:AS, IL-12) were capable of reducing the primary tumor size and the number of lung metastases, as well as improving overall mouse health and viability.
As shown in Figure 5 , mice that received RENCA tumor cells that had been transfected with mIL-12, AS alone or the ES:AS fusion protein developed significantly smaller primary tumors than control mice receiving either untransfected cells or cells transfected with empty vector alone (8 mice/group). The significant difference was first observed at day 17 post-injection and continued for the duration of the experiment. Whereas all of the mice that received AS or ES:AS eventually developed tumors, the results were particularly striking for mIL-12 in that only one of the eight mice receiving IL-12-transfected cells developed any tumor for the duration of the experiment.
Similar results were obtained using murine melanoma cells (B16F10). As compared to control mice that received mock transfected (no DNA), empty vector-transfected or cells transfected with eGFP as an irrelevant control, mice that received B16F10 tumor cells transfected with either mIL-12, AS or the ES:AS fusion protein developed significantly smaller primary tumors (Fig 6) . Differences between the animal groups were significant by days 21-23 post-injection; however, a marked trend towards decreased primary tumor burden was noted as early as days 14-15 post tumor injection. Overall, mIL-12 was most effective at inhibiting tumor development and one of the eight mice from this group remained tumor-free for the duration of the experiment. Furthermore, the ES:AS fusion protein was more effective than AS alone and was essentially comparable to mIL-12 ( Fig 6B) .
The B16F10 murine melanoma model is a wellcharacterized experimental system in which intravenously injected tumor cells tend to metastasize to the lung. 22 Although we injected tumors subcutaneously, we were also interested in knowing whether transfected primary tumor cells could affect the development of any lung metastases. Therefore, 23 days post tumor cell injection, mice were killed and lungs were collected. The number of lung metastases was counted using a dissecting microscope. As shown in Figure 7 , significantly fewer metastases were detected in those mice that received mIL-12-transfected cells (Po.05) and no metastases were detected in those that received either AS or ES:AS transfected cells (Po.01).
The overall mouse survival and health appeared to be strongly correlated with the extent of tumor burden and metastases. Mouse survival was monitored for 26 days. ) were seeded onto Transwell inserts placed atop wells containing 10,000 HUVEC growing on 0.5% gelatin, such that the cells shared a common supernatant without direct cell contact. bFGF (5 ng/ml) was added to induce HUVEC tube formation (no bFGF controls show baselines). After 2 days, a computer-assisted imaging program was used to quantitate the connectivity and total length of HUVEC tubes. AS-transfected cells reduced HUVEC tube formation by approximately 50% of the difference between no cells and no bFGF controls. As shown in Figure 8 , all of the mice that received either mIL-12 or ES:AS transfected B16F10 cells survived, and only one of the eight mice that received AS transfected cells had died at day 25. In contrast, control mice that received mock (no DNA) or eGFP (irrelevant DNA) transfected B16F10 cells had begun dying at day 21 post tumor injection. By days 25-26, approximately 40-60% of the control mice had succumbed to disease and died.
Discussion
In this study, we describe a nonviral cell transfection approach that is capable of rapidly and consistently transfecting two poorly immunogenic and hard-to-transfect murine tumor cells, RENCA and B16F10. DNA transfection is virtually instantaneous, with typical cell handling times on the order of several minutes. This technique is particularly useful when dealing with notoriously difficult-to-transfect cells, such as primary cells and certain tumor cells.
Using eGFP as a reporter gene, we achieved the efficient and safe transfection of both RENCA and B16F10 tumor cells. Marker gene expression was detected in approximately 80% of the cells, while the overall cell viability was 490%. The level of transgene expression in the tumor cells was remarkably consistent among multiple experiments. We detected significant levels of mIL-12 (200 ng/1e6cells/24 hour) and AS (250 ng/1e6cells/24 hour) protein in the transfected tumor cell conditioned supernatants. Though it is well known that electroporation mediates transient gene expression when stable selection is not involved, we found that by utilizing a DNA plasmid containing an EBNA1-oriP fragment from EBV transgene-mediated protein expression could be sustained up to 7 days. By this time, the tumor cells had become very confluent and started peeling off from the plate. In other studies, we found that longer duration of transgene expression could be observed using transfected primary cells, since these cells retain their contact inhibition of growth (i.e. monolayer formation), rather than overgrowing and peeling off the plates (data not shown). The reliability and efficacy of the transfection results obtained using our approach may support its applicability to gene discovery and validation protocols.
The efficacy of mIL-12 and AS was demonstrated in an in vitro cell-based assay as well as in vivo murine tumor models. We have also found that the transiently transfected cells can be cryopreserved and maintained functional transgene expression upon thawing after 6-month storage in liquid nitrogen (our unpublished observations). This makes it feasible to apply transfected tumor cells to more expanded protocols that require not only a single administration of cells, but rather multiple, consistent doses of transgene expression. Normally, a researcher must rely upon high-throughput in vitro screens to identify candidate genes, which must then be retested and validated in a separate in vivo study. Our approach could save valuable time in combining these two stages into a single valid approach.
The use of electroporation involves no toxic or costly materials. The cells are simply co-incubated with the plasmid DNA and rapidly processed in a suitable cellhandling volume. The speed of cell processing means that one should be able to rapidly transfect tumor cells with hundreds, if desired, of potentially novel genes for in vitro and/or in vivo identification. Several other studies have employed in vivo electroporation (direct electroporation of solid tumors) with some successes. For example, Cichon et al 23 used in vivo electroporation to administer the ES transgene into normal and neoplastic mouse tissues to treat RENCA as well as B16F10 melanoma. In that study, ES could similarly control primary and metastatic tumor development. Such studies suggest that the process of direct in vivo electroporation into the tumor tissue may hold promise for gene-based tumor therapies. Even so, we believe that the ex vivo approach of injecting transfected tumor cells offers significant advantages for the rapid, in vivo screening for gene discovery and validation. Whereas we achieved consistently high transfection efficiencies, in vivo electroporation of solid tumors has sometimes led to disappointing levels of transgene expression. 24 Secondly, an essentially pure population of tumor cells can be electroporated ex vivo, in contrast to somewhat mixed results in vivo. These two points are both likely due to inherent variability in the composition of solid tumors and degree of tumor-infiltrating cells and normal tissues. The ex vivo modification of tumor cells also eliminates the potential for nonspecific cellular responses by host cells adjacent to the electroporated area. Finally, the ex vivo modified tumor cells are capable of being administered into animals not only subcutaneously, but intravenously as well. This adds considerable flexibility into the experimental design of the protocol.
Although viral vectors, notably adenovirus, have been successfully used to transfer antiangiogenic genes (i.e. AS, ES, NK4) into tumor cells, [6] [7] [8] [9] [10] we believe that there are also considerable advantages in using a nonviral approach. First, the cost and time/labor involved in creating adenoviral vectors makes it less attractive for screening large numbers (i.e. cDNA libraries) of gene candidates. Secondly, fundamental to the purpose of screening in vivo, the antitumor effect must be specifically mediated by the transgene of interest, rather than by any potential secondary immune response against the viral antigen(s). 11 As mentioned previously, the electroporation-mediated delivery of the transgene(s) into the cells is virtually instantaneous. Following a brief (20 minutes) recovery period, the loaded cells are ready to be cultured in standard culturing media. In some cases, transgene expression can clearly be detected as early as 3-4 hours post-transfection. The loaded cells can safely and readily be used immediately or cryopreserved for subsequent (i.e. consistent) administration. From cell transfection to injections into animals, the entire process can be completed within 1-2 days for potentially hundreds of genes. This procedure was effectively accomplished due to the fact that the tumor cells could be efficiently transfected and that sufficient antiangiogenic and antineoplastic gene product was secreted.
An important consideration when using plasmid DNA vectors is the potential for bacterial sequences within the vector to cause pro-inflammatory responses in vivo. For instance, Sakurai et al 25 recently showed that CpG motifs normally contained within a DNA plasmid reduced lung nodules independently of any transgene expression. While we cannot rule out the potential for antitumor effects caused by the vector itself, we did perform careful statistical analyses between each of the experimental groups of animals. We found that the empty vector sometimes reduced tumor burden, but this was never significantly different from 'no DNA' controls (P ¼ 0.1-0.4 for Figures 5-7) . Furthermore, the empty vector most clearly had no effect in the RENCA model (Fig 5) and upon mouse survival in the B16 model (Fig 8) . In contrast, we show that each of the transgenes evaluated in our study consistently had antineoplastic effects that led to improved mouse survival. Ideally, DNA constructs lacking the bacterial backbone would be used for gene screening. We are currently exploring the possibility of obtaining mini-circle DNA vectors devoid of bacterial DNA, since these have recently been shown to result in persistent and high-level transgene expression. 26 Although plasmid DNA was used in this study, an electroporation-based approach is broadly capable of safely and effectively delivering other molecules to cells as well. For instance, we have previously shown that this approach can be used to deliver protein/peptide antigens, antibodies, oligonucleotides, siRNA, and large macromolecules, such as Dextran (MW 500 kDa), efficiently and safely to many other cell types. 27, 28 These molecules, once properly loaded into cells, are capable of altering biological responses, such as the antibody-mediated blocking of signal transduction pathways and the silencing of target gene expression by siRNA (our unpublished results). We therefore predict that this approach can be applied not only to antitumor gene discovery but also to those efforts aimed at screening large libraries of antibodies, peptides, drugs, and other molecules as well.
In summary, we have shown that this transient nonviral gene delivery approach is capable of delivering functional antiangiogenic and antineoplastic gene products to tumor cells. This approach could be a valuable tool for the rapid in vivo evaluation of other therapeutic gene candidates and also as a drug discovery tool for the screening of potentially novel molecules involved in almost any aspect of tumorigenesis.
